Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 21 January 2026 - 23 January 2026

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

New York, Jan 23, 2026, 05:47 (EST) — Premarket CRISPR Therapeutics AG shares slipped about 0.5% to $60.51 in premarket trading on Friday, following a sharp 11.1% gain the previous day. The stock closed at $60.81 on Thursday after hitting an intraday high of $60.86 and seeing over 3.4 million shares change hands. Investors were reacting to an insider-sale filing. (Public) The move highlighted just how volatile the stock remains. CRISPR is behaving more like a high-beta biotech than a reliable cash-flow play, with the tape influencing the price as much as its pipeline does. That’s crucial now, as investors
23 January 2026
····
Regencell Bioscience stock price jumps again: RGC up 16% premarket after 40% surge

Regencell Bioscience stock price jumps again: RGC up 16% premarket after 40% surge

New York, Jan 23, 2026, 05:30 EST — Premarket Regencell Bioscience Holdings Ltd shares climbed 16.3% to $35.77 in premarket trading Friday, building on a steep rise from the day before. (StockAnalysis) That’s important since premarket trading—before the 9:30 a.m. ET open—can amplify price swings, particularly in stocks that are already volatile during regular sessions. The stock jumped 40.4% on Thursday, closing at $30.77 after trading between $20.81 and $31.50, per price data. (Yahoo Finance) As of Friday, Regencell’s market cap stood near $15.2 billion, according to data from TradingView. Regencell remains at an early stage. Its most recent annual
23 January 2026
····
CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector

CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector

Sydney, Jan 23, 2026, 16:51 AEDT — After-hours CSL Ltd shares (CSL.AX) closed Friday 0.7% higher at A$179.62, building on Thursday’s 1.3% rise. The stock fluctuated between A$179.33 and A$180.80 during the session, with roughly 1.01 million shares traded. (Investing.com) The upward drift follows increased scrutiny on vaccine makers after broad U.S. policy shifts under Health Secretary Robert F. Kennedy Jr., impacting inoculation schedules and guidelines, analysts and investors caution. “Vaccines will not be a growth area under the current administration,” said Stephen Farrelly, ING’s global pharma and healthcare lead. Jefferies analyst Michael Leuchten noted a “clearly consumer reaction” to
23 January 2026
····
Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

New York, January 22, 2026, 18:46 EST — After-hours Moderna shares surged 4.2% to $51.87 in after-hours trading Thursday, following an earlier jump of about 11% to $55.17 on heavy volume—more than 34 million shares changed hands. CEO Stephane Bancel told Bloomberg TV the company won’t invest in new late-stage (Phase 3) vaccine trials, pointing to growing resistance from U.S. officials. He cautioned that the U.S. market is becoming less dependable. “You cannot make a return on investment if you don’t have access to the U.S. market,” Bancel said. (Reuters) Moderna’s pivot comes amid slumping demand for its COVID vaccines
23 January 2026
····
GRAIL stock jumps as Galleri outlook and FDA filing timeline come back into focus

GRAIL stock jumps as Galleri outlook and FDA filing timeline come back into focus

New York, Jan 22, 2026, 15:23 EST — Regular session Shares of GRAIL (GRAL.O) surged 13.2% to $114.41 Thursday afternoon, topping out at an intraday high of $118.50 earlier in the session. (Yahoo Finance) This shift is critical now since GRAIL is at a point where minor shifts in adoption and cash flow can rapidly alter forecasts. The company markets Galleri, a multi-cancer early detection blood test — a screening tool that still depends heavily on wider reimbursement and regulatory approval. Traders are focusing more on near-term indicators: how quickly Galleri volumes can rise without a matching surge in spending,
22 January 2026
···
Thermo Fisher stock price today: TMO steadies near a 52-week high ahead of Jan. 29 earnings

Thermo Fisher stock price today: TMO steadies near a 52-week high ahead of Jan. 29 earnings

New York, Jan 22, 2026, 13:34 (EST) — Regular session Thermo Fisher Scientific Inc (TMO) shares rose $2.03, or 0.3%, to $638.33 on Thursday afternoon, after briefly climbing as high as $643.66 earlier in the session. The stock is hovering near its best levels in a year as investors line up ahead of the company’s fourth-quarter and full-year 2025 results, due before the market opens on Jan. 29. Thermo Fisher said it will host a conference call that morning at 8:30 a.m. ET. (Thermo Fisher Scientific Investors) That timing matters for the life-sciences tools group, which tends to trade off
22 January 2026
·····
Regencell Bioscience (RGC) stock price jumps 37% again as the latest swing hits Nasdaq screens

Regencell Bioscience (RGC) stock price jumps 37% again as the latest swing hits Nasdaq screens

New York, Jan 22, 2026, 13:19 EST — Regular session Shares of Regencell Bioscience Holdings Limited jumped roughly 37% to $29.98 in afternoon trading Thursday, rebounding sharply from earlier dips. The stock swung between $20.91 and $30.78, with around 1 million shares changing hands by 1:19 p.m. EST. This move stands out because it follows a sharp drop in the opposite direction. Regencell shares fell 9.9% on Wednesday, closing at $21.91, highlighting the stop-start pattern that has made the stock tough to hold onto. (Barron’s) Thursday’s surge didn’t come with any fresh company filings on the SEC’s EDGAR platform. The
22 January 2026
·····
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

New York, Jan 22, 2026, 10:15 EST — Regular session Moderna shares climbed 7.7% to $53.65 Thursday morning, extending gains fueled by fresh long-term data on its experimental personalized cancer vaccine, created in partnership with Merck. Moderna’s push is vital as it aims to convince investors it can thrive beyond COVID vaccines. A promising mid-stage oncology trial could swiftly shift investor sentiment. Wall Street opened sharply higher after President Donald Trump softened his stance on tariffs targeting European countries. The Dow surged 0.81%, and the S&P 500 climbed 0.70% at the start of trading. (Reuters) Moderna and Merck revealed Tuesday
22 January 2026
····
Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

New York, Jan 22, 2026, 05:11 EST — Premarket Vertex Pharmaceuticals (VRTX) shares jumped 4.31%, closing Wednesday at $461.14 and marking their third straight session of gains. Trading volume climbed past the stock’s 50-day average. VRTX outperformed peers like AbbVie, Krystal Biotech, and Arcturus Therapeutics, while the S&P 500 and Dow each gained over 1%. (MarketWatch) Vertex is now under the spotlight ahead of its next major event: the company will release its fourth-quarter and full-year 2025 results after the U.S. market closes on Feb. 12, followed by a conference call and webcast at 4:30 p.m. ET. The company has
22 January 2026
·····
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

New York, Jan 22, 2026, 04:51 EST — Premarket. Moderna shares were flat at $49.81 in premarket trading on Thursday, after the stock jumped 15.8% in the previous session. (Yahoo Finance) The rally followed fresh five-year follow-up data on Moderna’s experimental personalised cancer vaccine used with Merck’s blockbuster immunotherapy Keytruda in high-risk melanoma, the companies said. (Merck.com) The move matters because Moderna is still trying to replace shrinking COVID-19 vaccine revenue with new products. Investors have been quick to reward any sign its mRNA technology can travel well beyond respiratory shots. In the update, the companies said the vaccine-Keytruda combination
22 January 2026
······
ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update

ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update

New York, January 21, 2026, 14:23 ET — Regular session ImmunityBio shares dropped roughly 2% to $6.35 in Wednesday afternoon trading, as investors pared back after the biotech’s recent regulatory update. The stock swung between $5.74 and $6.64, with around 67 million shares changing hands. The pullback is significant since the stock’s trajectory hinges on one key factor: how soon ImmunityBio can expand the U.S. label for Anktiva, its bladder-cancer immunotherapy on the market. A broader label would mean more patients gain access, especially in a treatment landscape that tightens quickly once standard options run out. ImmunityBio announced Tuesday that
21 January 2026
·····
Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

Corvus Pharmaceuticals stock whipsaws: CRVS slides after $150 million offering follows eczema data surge

New York, January 21, 2026, 05:35 ET — Premarket Shares of Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) dropped nearly 8%, slipping to $19.68 in premarket trading Wednesday. The decline follows the company’s announcement of an underwritten public offering worth $150 million in common stock and pre-funded warrants. These warrants let investors lock in shares now by paying most of the price upfront, with the option to buy later. Jefferies and Goldman Sachs are heading the deal, which also includes a 30-day over-allotment option allowing underwriters to purchase an extra $22.5 million in shares. (markets.businessinsider.com) The timing is key. Corvus is set
21 January 2026
·····
1 2 3 4 5 … 25

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:22 AM EST Dollar Dips as Stocks Rally and US Data Influences Fed Rate Expectations February 7, 2026, 12:18 AM EST. The **dollar index** fell 0.17%, pressured by a rebound in equity markets reducing demand for the safe-haven currency. Weaker-than-expected U.S. labor market data raised the odds of a Fed rate cut to 18% for March, though consumer sentiment improved to a six-month high, limiting losses. Hawkish comments from Atlanta Fed's Raphael Bostic emphasized maintaining restrictive monetary policy. The dollar faces medium-term weakness amid expectations for rate cuts
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop